CAR T-cell Therapy for Myeloid Leukemia| A Pipeline Analysis Report 2018| Technavio

Technavio has published a new report on the drug development pipeline for CAR T-cell therapy for myeloid leukemia, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

LONDON--()--Technavio has announced their latest pipeline analysis report on the CAR T-cell therapy for myeloid leukemia market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat CAR T-cell therapy for myeloid leukemia.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

CAR T-cell therapy for myeloid leukemia: Market overview

Leukemia is the cancer blood cells. In leukemia, the damaged cells do not die at the same rate as the normal cells. It causes the accumulation of damaged cells, thus reducing the space for the normal cells to function and survive. Leukemia can either develop and worsen quickly or over a period of time. It is highly fatal; however, with extensive research in oncology, various methods are evolving to treat and control the growth of the disease.

According to a senior analyst at Technavio for research on oncology, “In CAR T-cell therapy, the patient’s T-cells are genetically modified in the laboratory by adding chimeric antigen receptor to bind to these cells, which attack the cancer cells. These receptors graft onto a monoclonal antibody onto a T-cell. Various CAR T-cell therapies are being developed for both forms of leukemia, as the pre-clinical studies have suggested that they are more effective against the cancer cells.”

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

CAR T-cell therapy for myeloid leukemia: Segmentation analysis

This market research report segments the CAR T-cell therapy for myeloid leukemia market based on therapies employed that includes monotherapy and monotherapy+combination therapy, RoA (intravenous and undisclosed), therapeutic modalities (cell), targets for drugs under development (CD19, CD7, CD123, CD33, and undisclosed), drugs under development (phase I and phase I/II), and recruitment status (recruiting, not yet recruiting, and completed). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Some of the key topics covered in the report are:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age
  • Recruitment volume

Key Companies

  • Type of players
  • Company Overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

Technavio has published a new report on the drug development pipeline for CAR T-cell therapy for myeloid leukemia.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com